Kisoji Biotechnologie Inc.: federal grants and contributions: 6 agreements; $2.1M value; 1 departments; 2 programs.
Assay record ASY-CA-1QN9Z7V0SD · Cite as: Assay Systems, “Kisoji Biotechnologie Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/kisoji-biotechnologie-inc/
Through the development and application of cutting-edge machine learning algorithms, the firm seek to build an end-to-end AI-enabled platform, KisoSeek, that will use machine learning to search and identify therapeutic cancer antibodies.
The firm will use machine learning to predict the 3D structure of antibodies more accurately and rapidly than existing technologies. A tool will be developed to provide antibody structures. The enhanced AI-enabled platform will be used to search and identify therapeutic antibodies.
Cancer remains a very important disease in North America and the world. Antibodies have emerged as an effective treatment for cancer. KisoJi is developing antibodies for treatment of newly diagnosed cancers and for previously treated cancers.
The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.
As part of Multinational Corporate Collaboration Program, the project “KisoJi Biotechnology Inc. Research Collaboration” will focus on solidifying a partnership with a large multinational corporation and further developing the scope of a larger R&D collaboration project.
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.